Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17572995 | 0.87 | MCHR1 (0.54) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL17559448 | 0.86 | MCHR1 (0.53) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL6538705 | 0.86 | CCR5 (0.57) | MCHR1PDK2L3MBTL3NPY5RCCR5 | |
| SCHEMBL94337 | 0.85 | MCHR1 (0.50) | MCHR1PDK2USP30CCR5 | |
| Lithium Ion SCHEMBL17559446 | 0.84 | MCHR1 (0.52) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL94743 | 0.84 | L3MBTL3 (0.57) | PDK2L3MBTL3USP30SMOCCR5 | |
| SCHEMBL17559476 | 0.83 | PDK2 (0.52) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL95169 | 0.80 | ALDH1A1 (0.58) | — | |
| SCHEMBL20772948 | 0.78 | MCHR1 (0.47) | MCHR1PDK2L3MBTL3NPY5R | |
| SCHEMBL562825 | 0.76 | POLB (0.50) | MCHR1PDK2L3MBTL3NPY5RSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | MCHR1 4289/4885PDK2 2251/4885L3MBTL3 1998/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | MCHR1 1377/4885PDK2 2311/4885L3MBTL3 889/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | MCHR1 1377/4885PDK2 2311/4885L3MBTL3 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.